# Pulmonx Corp (LUNG)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/pulmonx-corp/ JSON: https://steadybase.io/company/pulmonx-corp.json Checked Nov 10, 2026. Latest filing read: Nov 3, 2026.

## Company

- Legal name: Pulmonx Corp
- Ticker: LUNG (Nasdaq)
- SEC CIK: 0001127537
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Redwood City, CA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: pulmonx.com
- LinkedIn: https://www.linkedin.com/company/pulmonx
- Next earnings date: Nov 11, 2026

## Key facts

- Revenue: $90.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/0001127537-26-000015-index.html
- Operating income: -$53.7M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/0001127537-26-000015-index.html
- Net income: -$54.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/0001127537-26-000015-index.html
- SG&A: $101.3M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/0001127537-26-000015-index.html
- Employees: 296 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- Shares outstanding: 43,550,665 as of Oct 29, 2026 (10-Q filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000048/0001127537-26-000048-index.html
- Auditor: Bdo Usa, P.C., San Francisco, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm

## Business

We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). Our solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $90.5M | -$53.7M | -$54.0M | $101.3M |
| Dec 31, 2024 | $83.8M | -$57.7M | -$56.4M | $102.1M |
| Dec 31, 2023 | $68.7M | -$61.9M | -$60.8M | $94.6M |
| Dec 31, 2022 | $53.7M | -$58.6M | -$58.9M | $83.1M |
| Dec 31, 2021 | $48.4M | -$47.3M | -$48.7M | $69.9M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/pulmonx-corp.json

## Officers and directors

- Glen French, President and Chief Executive Officer of Pulmonx. LinkedIn: https://linkedin.com/in/glen-french-565a0161. Source: 8-K filed Oct 27, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000042/lung3q26earningsrelease102.htm
- Glendon E. French III, President and CEO. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000180562426000004/0001805624-26-000004-index.htm
- Derrick Sung, Chief Operating Officer and Chief Financial Officer. LinkedIn: https://linkedin.com/in/derrick-sung-a848161. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- David Aaron Lehman, General Counsel. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000135422826000005/0001354228-26-000005-index.htm
- Geoffrey Beran Rose, Chief Commercial Officer. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000180414626000004/0001804146-26-000004-index.htm
- Srikanth Radhakrishnan, Chief Science & Techn. Officer. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000209867826000004/0002098678-26-000004-index.htm
- Dana G. Mead, Jr., Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- Daniel P. Florin, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- Georgia Garinois-Melenikiotou, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- Richard Ferrari, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- Thomas W. Burns, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- Tiffany Sullivan, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- David Lehman, Named in proxy. Source: DEF 14A filed Apr 22, 2026, https://www.sec.gov/Archives/edgar/data/1127537/000114036126016105/ny20064182x1_def14a.htm

## Recent 8-K events

- Oct 27, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000042/lung-20261027.htm
- Jul 29, 2026: Item 2.02, Results of operations and financial condition (earnings release). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000035/lung-20260729.htm
- Jun 4, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000031/lung-20260604.htm
- Apr 29, 2026: Item 2.02, Results of operations and financial condition (earnings release). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/lung-20260429.htm
- Mar 5, 2026: Item 1.01, Entry into a material definitive agreement; Item 1.02, Termination of a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 3.02, Unregistered sales of equity securities; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1127537/000119312526092064/d126478d8k.htm
- Mar 4, 2026: Item 2.02, Results of operations and financial condition (earnings release). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000003/lung-20260304.htm
- Nov 12, 2025: Item 2.02, Results of operations and financial condition (earnings release). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000058/lung-20251112.htm
- Oct 27, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000052/lung-20251021.htm
- Jul 30, 2025: Item 2.02, Results of operations and financial condition (earnings release). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000041/lung-20250730.htm
- May 23, 2025: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000028/lung-20250522.htm

## Insider trades (Form 4)

- Sep 1, 2026: Srikanth Radhakrishnan (Chief Science & Techn. Officer) sold 14,245 shares, about $32,194. Source: https://www.sec.gov/Archives/edgar/data/1127537/000209867826000004/0002098678-26-000004-index.htm
- Sep 1, 2026: Glendon E. French III (President and CEO) sold 41,882 shares, about $94,653. Source: https://www.sec.gov/Archives/edgar/data/1127537/000180562426000004/0001805624-26-000004-index.htm
- Sep 1, 2026: Geoffrey Beran Rose (Chief Commercial Officer) sold 7,879 shares, about $17,807. Source: https://www.sec.gov/Archives/edgar/data/1127537/000180414626000004/0001804146-26-000004-index.htm
- Sep 1, 2026: David Aaron Lehman (General Counsel) sold 14,334 shares, about $32,395. Source: https://www.sec.gov/Archives/edgar/data/1127537/000135422826000005/0001354228-26-000005-index.htm
- Jun 2, 2026: Glendon E. French III (President and CEO) sold 56,149 shares, about $86,875. Source: https://www.sec.gov/Archives/edgar/data/1127537/000180562426000002/0001805624-26-000002-index.htm
- Jun 1, 2026: Srikanth Radhakrishnan (Chief Science &Techn. Officer) sold 14,497 shares, about $22,325. Source: https://www.sec.gov/Archives/edgar/data/1127537/000209867826000002/0002098678-26-000002-index.htm
- Jun 1, 2026: Geoffrey Beran Rose (CHIEF COMMERCIAL OFFICER) sold 8,023 shares, about $12,355. Source: https://www.sec.gov/Archives/edgar/data/1127537/000180414626000002/0001804146-26-000002-index.htm
- Jun 1, 2026: David Aaron Lehman (GENERAL COUNSEL) sold 14,594 shares, about $22,475. Source: https://www.sec.gov/Archives/edgar/data/1127537/000135422826000003/0001354228-26-000003-index.htm
- Mar 2, 2026: Srikanth Radhakrishnan (Chief Science &Techn. Officer) sold 10,483 shares, about $14,991. Source: https://www.sec.gov/Archives/edgar/data/1127537/000209867826000001/0002098678-26-000001-index.htm
- Mar 2, 2026: Glendon E. French III (President and CEO) sold 67,813 shares, about $96,973. Source: https://www.sec.gov/Archives/edgar/data/1127537/000180562426000001/0001805624-26-000001-index.htm
- Mar 2, 2026: Geoffrey Beran Rose (CHIEF COMMERCIAL OFFICER) sold 7,732 shares, about $11,057. Source: https://www.sec.gov/Archives/edgar/data/1127537/000180414626000001/0001804146-26-000001-index.htm
- Mar 2, 2026: David Aaron Lehman (GENERAL COUNSEL) sold 12,237 shares, about $17,499. Source: https://www.sec.gov/Archives/edgar/data/1127537/000135422826000002/0001354228-26-000002-index.htm
- Dec 8, 2025: Daniel P. Florin (Director) sold 23,321 shares, about $46,409. Source: https://www.sec.gov/Archives/edgar/data/1127537/000140245925000005/0001402459-25-000005-index.htm
- Dec 1, 2025: Glendon E. French III (President and CEO) sold 8,805 shares, about $13,824. Source: https://www.sec.gov/Archives/edgar/data/1127537/000180562425000005/0001805624-25-000005-index.htm
- Dec 1, 2025: Geoffrey Beran Rose (CHIEF COMMERCIAL OFFICER) sold 6,322 shares, about $9,926. Source: https://www.sec.gov/Archives/edgar/data/1127537/000180414625000004/0001804146-25-000004-index.htm

## What management said

- "We are very pleased to have returned to year-over-year revenue growth in the third quarter. We continue to execute on our commercial strategy, advance our clinical initiatives, and deliver the operating leverage we expected" Glen French, President and Chief Executive Officer of Pulmonx (8-K filed Oct 27, 2026). Source: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000042/lung3q26earningsrelease102.htm

## Latest filings

- 8-K filed Oct 27, 2026: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000042/lung-20261027.htm
- 10-K filed Mar 10, 2026: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000015/lung-20251231.htm
- 10-Q filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000048/lung-20260930.htm
- DEF 14A filed Apr 22, 2026: https://www.sec.gov/Archives/edgar/data/1127537/000114036126016105/ny20064182x1_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/